Dabuzalgron

SKU: orb1309790

Description

Dabuzalgron (Ro 115-1240) is a selective α1A-adrenoceptor agonist used in research for urinary incontinence. Studies indicate it also exhibits a cardioprotective role in models of doxorubicin-induced cardiotoxicity by preserving mitochondrial function, relevant for in vivo and in vitro pharmacological investigations.

Research Area

Cell Biology, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 219311-44-1
• MW: 317.79
• Purity: 98.35% (May vary between batches)
• Formula: C₁₂H₁₆ClN₃O₃S
• SMILES: Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O
• Target: Adrenergic Receptor,Apoptosis
• Solubility: DMSO:25 mg/mL (78.67 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.29 mM)

Bioactivity

• In Vivo:
  Dabuzaron (10μg / kg; oral tube; twice daily; 7 consecutive days; C57B16J wild-type or α1A-AR gene knockout mice) treatment can prevent DOX cardiotoxicity by activating α1A-AR. Dabuzaron prevents mitochondrial function-related transcript reduction, up-regulates PGC1α, retains ATP content, and reduces oxidative stress in DOX-treated mouse hearts.
  Read more...
• In Vitro:
  Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM. ERK1 / 2 activation helps Dabuzaron's cardioprotection. Dabuzaron (10 μM; 4 hours) protects NRVM from cell death caused by doxorubicin (DOX). Dabuzaren (10 μM; 4 hours) activation of α1A-AR alleviates the harmful effects of DOX on mitochondrial membrane potential and eliminates the activation of important elements of the apoptotic response to mitochondrial damage.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Dabuzalgron, Cell, Beta Receptor, AdrenergicReceptor, Adrenergic Receptor, Apoptosis, mitochondrial, inhibit, incontinence, death, Inhibitor, membrane, α1A-adrenergic receptor, urinary, Ro 115-1240, potential

Compound Identifiers

PubChem CID

216249